Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). The most...
11 KB (810 words) - 06:23, 15 July 2024
hypereosinophilic leukemia Monoclonal antibodies such as dupilumab and lebrikizumab target IL-13 and its receptor, which reduces eosinophilic inflammation...
28 KB (3,105 words) - 16:05, 11 July 2024
that use anti-IL-13 monoclonal antibodies include tralokinumab, and lebrikizumab. These treatments have shown improvements in asthma patients, yet there...
20 KB (2,271 words) - 04:25, 12 May 2024
Cintredekin besudotox Interleukin 4 Interleukin 13 Antibodies: Anrukinzumab Lebrikizumab Tralokinumab IL-15 Agonists: ALT-803 Interleukin 15 IL-17 Agonists: Interleukin...
22 KB (1,789 words) - 04:29, 16 July 2024
announced its acquisition of Dermira for $1.1 billion, gaining control of lebrikizumab,glycopyrronium cloth used in the treatment of hyperhidrosis, and other...
165 KB (15,022 words) - 21:30, 26 July 2024
are approved to treat moderate-to-severe eczema in the US and the EU. Lebrikizumab is also approved in the EU for treating moderate-to-severe AC but in...
90 KB (9,340 words) - 03:59, 29 July 2024
Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab†Lebrikizumab Olokizumab†Perakizumab Risankizumab Spesolimab Tildrakizumab Veterinary...
38 KB (4,304 words) - 10:14, 21 July 2024
Cintredekin besudotox Interleukin 4 Interleukin 13 Antibodies: Anrukinzumab Lebrikizumab Tralokinumab IL-15 Agonists: ALT-803 Interleukin 15 IL-17 Agonists: Interleukin...
22 KB (2,508 words) - 16:48, 29 July 2024
Cintredekin besudotox Interleukin 4 Interleukin 13 Antibodies: Anrukinzumab Lebrikizumab Tralokinumab IL-15 Agonists: ALT-803 Interleukin 15 IL-17 Agonists: Interleukin...
43 KB (3,662 words) - 19:35, 12 July 2024
blockers: Benralizumab Mepolizumab Reslizumab IL-13-specific blockers: Lebrikizumab Tralokinumab Dual IL-4 and IL-13 blockers: Dupilumab IgE-blockers: Ligelizumab...
5 KB (560 words) - 00:25, 17 July 2024